Quantcast

Latest Galectin Stories

2014-08-28 12:29:51

NEW YORK, Aug. 27, 2014 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of investors who purchased Galectin Therapeutics Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) securities between January 6, 2014 and July 28, 2014. http://photos.prnewswire.com/prnvar/20120409/MM84375LOGO For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt....

2014-08-06 16:28:13

WILMINGTON, Del., Aug. 6, 2014 /PRNewswire/ -- Rigrodsky & Long, P.A.: -- Do you, or did you, own shares of Galectin Therapeutics Inc. (NASDAQ CM: GALT)? -- Did you purchase your shares before January 6, 2014, or between January 6, 2014 and July 28, 2014, inclusive? -- Did you lose money in your investment in Galectin Therapeutics Inc.? -- Do you want to discuss your rights? Rigrodsky & Long, P.A., including former Special Assistant United...

2014-07-30 12:31:04

WAYNE, Pa., July 30, 2014 /PRNewswire/ -- Ryan & Maniskas, LLP has commenced an investigation into potential securities law violations by certain officers of Galectin Therapeutics, Inc. ("Galectin" or the "Company") (NASDAQ: GALT). http://photos.prnewswire.com/prnvar/20121112/MM11729LOGO Galectin shareholders who purchased Galectin shares should contact Richard A. Maniskas, Esquire at 877-316-3218 or at rmaniskas@rmclasslaw.com to learn more about this investigation or visit:...

2014-07-30 12:30:06

NEW YORK, July 30, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Galectin Therapeutics, Inc. ("Galectin Therapeutics" or the "Company") (NasdaqCM: GALT). Such investors are advised to contact Edward N. Gewirtz or his investor relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. The investigation focuses on whether the Company and certain of its...

2012-01-22 18:00:00

La Jolla acquires GCS-100 for treatment of cancer and chronic organ failure, appoints new CEO and director Scottsdale, AZ (PRWEB) January 22, 2012 QualityStocks would like to highlight La Jolla Pharmaceutical Co., a publicly traded biopharmaceutical company dedicated to the development of treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company´s product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular...

2009-06-15 08:00:00

WELLESLEY HILLS, Mass., June 15 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") announced today that in vitro studies have demonstrated that GCS-100 binds to and blocks the effects of galectin-3. Galectin-3 plays an important role in tumor cell survival, new blood vessel growth, cell proliferation and tumor metastasis, which is the spread of cancer beyond its primary site. As a result, this product candidate may have multiple benefits in combating cancer cells, including: Induction...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related